Navigation Links
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
Date:9/2/2008

SAN FRANCISCO, Sept. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Wednesday, September 3, to discuss partnering plans for Dimebon.

Teleconference/Webcast Details

To participate in the live call on Wednesday, September 3, at 8:30 a.m. Eastern Time by telephone, please dial 877-681-3375 from the U.S. or +1-719-325-4933 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medivation Announces Participation in Upcoming Conferences
2. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
3. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
4. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Senior Management Promotions
7. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
8. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
10. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
11. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... EXTON, Pa., June 2 ViroPharma Incorporated (Nasdaq: ... and chief scientific officer of ViroPharma, will present at the ... ET on Tuesday, June 9, 2009. The conference is ... , , ViroPharma also announced that William Roberts, vice ...
... College Troy campus ... , TROY, Mich., June 2 Walsh College ... to offer a new series of Walsh College,s successful "Take Charge" workshops for ... days, more topics and expanded career content. All are provided at no ...
... 2 Cynosure, Inc. (Nasdaq: CYNO ... aesthetic treatment systems, today announced that President and Chief Executive Officer Michael ... the following investor conferences in New York City this month: , ... Gabelli & Company Healthcare Symposium , Tuesday, June 9; ...
Cached Biology Technology:ViroPharma to Present at Two June Healthcare Conferences 2Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of 'Take Charge' Workshops for the Unemployed 2Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of 'Take Charge' Workshops for the Unemployed 3Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of 'Take Charge' Workshops for the Unemployed 4Cynosure Announces Presentations at Upcoming Investor Conferences 2
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... January 19 Mexican business leader Carlos Slim Hel today ... medicine that will help accelerate progress in public health in ... carried out by the Carlos Slim Institute of Health in ... the National Institute for Genomic Medicine of the Mexican Secretariat ...
... is "Molecule of the Year 2009". This was announced ... Society for Molecular and Cell Biology and Biotechnology Protocols ... Zsuzsanna Izsvk, Dr. Zoltn Ivics and Dr. Lajos Mts ... Berlin-Buch. According to the jury, it was selected out ...
... a specific form of a gene that puts them on ... of cancer, according to a new study by scientists at ... proto-oncogene is activated in a variety of tumor malignancies. The ... a role in neurodevelopment, which is why Katherine E. Burdick, ...
Cached Biology News:Mexico-US collaboration launched to study major human diseases 2'Sleeping Beauty' -- Molecule of the Year 2Gene linked to schizophrenia may reduce cancer risk 2
... Versatile state of the Art GLP ... to dual 38,000 L fermentation. ... to production. Aseptic operation capable ... Fed-Batch, and Continuous Modes. Hosts ...
... 200 g of lyophilized peptide derived from ... acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptide ... of Cayman's EP1 receptor polyclonal antibody (Catalog ... conjunction with this antibody to block protein-antibody ...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Complete cell culture media with cytokines...
Biology Products: